Printer Friendly, PDF & Email Printer Friendly, PDF & Email

§170.315(b)(2) Clinical information reconciliation and incorporation

Updated on 09-11-2023
Version # Description of Change Version Date
1.0

Final Test Procedure.
06-01-2020
1.1

Compliance date updated per the IFR, Information Blocking and the ONC Health IT Certification Program: Extension of Compliance Dates and Timeframes in Response to the COVID-19 Public Health Emergency. 
11-02-2020
1.2

Updated to include approved Standards Version Advancement Process (SVAP) standards for 2022.
08-29-2022
1.3

Updated to include the Standards Version Advancement Process (SVAP) Approved Standards for 2023.
09-11-2023
Regulation Text
Regulation Text

§ 170.315 (b)(2) Clinical information and reconciliation and incorporation—

  1. General requirements. Paragraphs (b)(2)(ii) and (iii) of this section must be completed based on the receipt of a transition of care/referral summary formatted in accordance with the standards adopted in § 170.205(a)(3) through (5) using the Continuity of Care Document, Referral Note, and (inpatient setting only) Discharge Summary document templates on and after December 31, 2022.
  2. Correct patient. Upon receipt of a transition of care/referral summary formatted according to the standards adopted § 170.205(a)(3) through (5), technology must be able to demonstrate that the transition of care/referral summary received can be properly matched to the correct patient.
  3. Reconciliation. Enable a user to reconcile the data that represent a patient's active medication list, allergies and intolerance list, and problem list as follows. For each list type:
    1. Simultaneously display (i.e., in a single view) the data from at least two sources in a manner that allows a user to view the data and their attributes, which must include, at a minimum, the source and last modification date.
    2. Enable a user to create a single reconciled list of each of the following: Medications; Allergies and Intolerances; and problems.
    3. Enable a user to review and validate the accuracy of a final set of data.
    4. Upon a user's confirmation, automatically update the list, and incorporate the following data expressed according to the specified standard(s) on and after December 31, 2022:
      1. Medications. At a minimum, the version of the standard specified in § 170.213;
      2. Allergies and intolerance. At a minimum, the version of the standard specified in § 170.213; and
      3. Problems. At a minimum, the version of the standard specified in § 170.213.
  4. System verification. Based on the data reconciled and incorporated, the technology must be able to create a file formatted according to the standard specified in § 170.205(a)(4) using the Continuity of Care Document template and the standard specified in § 170.205(a)(5) on and after December 31, 2022.
Standard(s) Referenced

Paragraphs (b)(2)(i) and (ii)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

§ 170.205(a)(3) Health Level 7 (HL7®)  Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1 (US Realm) Draft Standard for Trial Use July 2012

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

Paragraphs (b)(2)(iii)(B) – (D)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

Paragraph (b)(2)(iv)

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

 

Standards Version Advancement Process (SVAP) Version(s) Approved 

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 4.1 - US Realm, June 2023

§ 170.213 United States Core Data for Interoperability (USCDI), Version 3, October 2022 Errata

The following are available for certification until December 31, 2023:

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

§ 170.213 United States Core Data for Interoperability (USCDI), Version 2, July 2021

For more information, please visit the Standards Version Advancement Process (SVAP) Version(s) page.

Resource Documents
Resource Document
Revision History
Version # Description of Change Version Date
1.0

Final Test Procedure.
06-01-2020
1.1

Compliance date updated per the IFR, Information Blocking and the ONC Health IT Certification Program: Extension of Compliance Dates and Timeframes in Response to the COVID-19 Public Health Emergency. 
11-02-2020
1.2

Updated to include approved Standards Version Advancement Process (SVAP) standards for 2022.
08-29-2022
1.3

Updated to include the Standards Version Advancement Process (SVAP) Approved Standards for 2023.
09-11-2023
Regulation Text
Regulation Text

§ 170.315 (b)(2) Clinical information and reconciliation and incorporation—

  1. General requirements. Paragraphs (b)(2)(ii) and (iii) of this section must be completed based on the receipt of a transition of care/referral summary formatted in accordance with the standards adopted in § 170.205(a)(3) through (5) using the Continuity of Care Document, Referral Note, and (inpatient setting only) Discharge Summary document templates on and after December 31, 2022.
  2. Correct patient. Upon receipt of a transition of care/referral summary formatted according to the standards adopted § 170.205(a)(3) through (5), technology must be able to demonstrate that the transition of care/referral summary received can be properly matched to the correct patient.
  3. Reconciliation. Enable a user to reconcile the data that represent a patient's active medication list, allergies and intolerance list, and problem list as follows. For each list type:
    1. Simultaneously display (i.e., in a single view) the data from at least two sources in a manner that allows a user to view the data and their attributes, which must include, at a minimum, the source and last modification date.
    2. Enable a user to create a single reconciled list of each of the following: Medications; Allergies and Intolerances; and problems.
    3. Enable a user to review and validate the accuracy of a final set of data.
    4. Upon a user's confirmation, automatically update the list, and incorporate the following data expressed according to the specified standard(s) on and after December 31, 2022:
      1. Medications. At a minimum, the version of the standard specified in § 170.213;
      2. Allergies and intolerance. At a minimum, the version of the standard specified in § 170.213; and
      3. Problems. At a minimum, the version of the standard specified in § 170.213.
  4. System verification. Based on the data reconciled and incorporated, the technology must be able to create a file formatted according to the standard specified in § 170.205(a)(4) using the Continuity of Care Document template and the standard specified in § 170.205(a)(5) on and after December 31, 2022.
Standard(s) Referenced

Paragraphs (b)(2)(i) and (ii)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

§ 170.205(a)(3) Health Level 7 (HL7®)  Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1 (US Realm) Draft Standard for Trial Use July 2012

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

Paragraphs (b)(2)(iii)(B) – (D)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

Paragraph (b)(2)(iv)

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

 

Standards Version Advancement Process (SVAP) Version(s) Approved 

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 4.1 - US Realm, June 2023

§ 170.213 United States Core Data for Interoperability (USCDI), Version 3, October 2022 Errata

The following are available for certification until December 31, 2023:

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

§ 170.213 United States Core Data for Interoperability (USCDI), Version 2, July 2021

For more information, please visit the Standards Version Advancement Process (SVAP) Version(s) page.

Testing
Testing Tool

 

 

Edge Testing Tool (ETT): Message Validators

 

 

Test Tool Documentation

Test Tool Supplemental Guide

Criterion Subparagraph Test Data
(b)(2)(ii)

170.315_b2_ciri_r11_sample*.xml (All Samples)

170.315_b2_ciri_r21_sample*.xml (All Samples)
(b)(2)(iii)

170.315_b2_ciri_r11_sample*.xml (All Samples)

170.315_b2_ciri_r11_ sample*_recon*.xml (All Samples)

170.315_b2_ciri_r21_sample*.xml (All Samples)

170.315_b2_ciri_r21_sample*_recon*.xml (All Samples)

Please consult the Final Rule entitled 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program and the Interim Final Rule (IFR) Information Blocking and the ONC Health IT Certification Program: Extension of Compliance Dates and Timeframes in Response to the COVID-19 Public Health Emergency, for a detailed description of the certification criterion with which these testing steps are associated. Developers are encouraged to consult the Certification Companion Guide in tandem with the Test Procedure, as they both provide clarifications that may be useful for product development and testing.

Note: The order in which the test steps are listed reflects the sequence of the certification criterion and does not necessarily prescribe the order in which the test should take place.

Testing components

Documentation Icon No Visual Inspection Icon Test Tool Icon ONC Supplied Test Data Icon SVAP Icon

Paragraph (b)(2) – (Conditional – For Modules Certified to 2015 Edition (b)(2))

System Under Test

A Health IT Module currently certified to the 2015 Edition § 170.315(b)(2) Clinical information reconciliation and incorporation will attest directly to the ONC-ACB to conformance with the updated § 170.315(b)(2) requirements outlined in the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program Final Rule.

Test Lab Verification

The ONC-ACB verifies the Health IT Module certified to 2015 Edition § 170.315(b)(2) Clinical information reconciliation and incorporation attests conformance to 2015 Edition Cures Update § 170.315(b)(2) criterion requirements.

System Under Test
ONC-ACB Verification

A Health IT Module currently certified to the 2015 Edition § 170.315(b)(2) Clinical information reconciliation and incorporation will attest directly to the ONC-ACB to conformance with the updated § 170.315(b)(2) requirements outlined in the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program Final Rule.

The ONC-ACB verifies the Health IT Module certified to 2015 Edition § 170.315(b)(2) Clinical information reconciliation and incorporation attests conformance to 2015 Edition Cures Update § 170.315(b)(2) criterion requirements.

Paragraph (b)(2)(ii)

System Under Test

Setup

  1. Using the Edge Testing Tool (ETT): Message Validators –C-CDA R2.1 2015 Edition Cures Update, the user selects the receiver “170.315_b2_CIRI_Amb ” or “170.315_b2_CIRI_Inp” criteria, selects one of the C-CDA 2.1 xml files, and executes the download of the required Clinical Information Reconciliation document 170.315_b2_ciri_r21_sample*.xml file for C-CDA R 2.1.
  2. The user repeats step 1, but selects the corresponding CDA R1.1, xml file from the File Name and executes the download of the required Clinical Information Reconciliation document 170.315_b2_ciri_r11_sample*.xml file for C-CDA R1.1, or

 

     Setup (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

 

Correct Patient

  1. Using the xml files downloaded in step 1, the user demonstrates that a transition of care summary/referral summary Consolidated-Clinical Document Architecture (C-CDA) document, formatted according to the standard adopted at § 170.205(a)(3) HL7® Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1, can be properly matched to a patient in the Health IT Module. Note that matches can be made automatically or manually.
  2. Using the xml files downloaded in step 2, the user demonstrates that a transition of care summary/referral summary C-CDA document can be properly matched to a patient in the Health IT Module automatically or manually formatted according to the standards adopted at:
    • § 170.205(a)(4), HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, DSTU Release 2.1, and
    • § 170.205(a)(5), HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2 Companion Guide, Release 2

 

      Correct Patient (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

 

      5. The user repeats steps 1-4, for each set of C-CDA R1.1, and C-CDA R2.1 xml files listed in the File Name for each of the health IT settings being certified.

Test Lab Verification

Setup

  1. The tester creates a version in human readable format of the downloaded C-CDA R2 Release 2.1, in accordance with § 170.213 from step 1, of the System Under Test to be used for verification.
  2. The tester creates a human readable version of the downloaded C-CDA R2 Release 1.1, files from step 2, of the System Under Test to be used for verification.

Correct Patient

  1. The tester uses visual inspection to verify the Health IT Module can receive the C-CDA document downloaded in step 1, of the System Under Test as a C-CDA Release 1.1, document formatted according to the standard specified in § 170.205(a)(3) as either a CCD or a C-CDA with no specific document template.
  2. The tester uses visual inspection to verify the Health IT Module can receive the C-CDA document downloaded in step 2, of the System Under Test as a C-CDA Release 2.1, document formatted according to the standard specified in § 170.205(a)(4) using one of the following document templates:
    • CCD;
    • Referral Note; and
    • Inpatient setting only: Discharge Summary.
  3. Using the Health IT Module and the human readable xml files from steps 1 and 2, the tester verifies that each of the received C-CDA Release 1.1 and Release 2.1, documents can be properly matched to the correct patient record.

Paragraph (b)(2)(i)

Paragraphs (b)(2)(ii) and (iii) of this section must be completed based on the receipt of a transition of care/referral summary formatted in accordance with the standards adopted in § 170.205(a)(3) HL7® Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1 and § 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, DSTU Release 2.1 using the Continuity of Care Document (CCD), Referral Note, and (inpatient setting only) Discharge Summary document templates.

System Under Test Test Lab Verification

Setup

  1. Using the Edge Testing Tool (ETT): Message Validators –C-CDA R2.1 2015 Edition Cures Update, the user selects the receiver “170.315_b2_CIRI_Amb ” or “170.315_b2_CIRI_Inp” criteria, selects one of the C-CDA 2.1 xml files, and executes the download of the required Clinical Information Reconciliation document 170.315_b2_ciri_r21_sample*.xml file for C-CDA R 2.1.
  2. The user repeats step 1, but selects the corresponding CDA R1.1, xml file from the File Name and executes the download of the required Clinical Information Reconciliation document 170.315_b2_ciri_r11_sample*.xml file for C-CDA R1.1, or

 

     Setup (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

 

Correct Patient

  1. Using the xml files downloaded in step 1, the user demonstrates that a transition of care summary/referral summary Consolidated-Clinical Document Architecture (C-CDA) document, formatted according to the standard adopted at § 170.205(a)(3) HL7® Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1, can be properly matched to a patient in the Health IT Module. Note that matches can be made automatically or manually.
  2. Using the xml files downloaded in step 2, the user demonstrates that a transition of care summary/referral summary C-CDA document can be properly matched to a patient in the Health IT Module automatically or manually formatted according to the standards adopted at:
    • § 170.205(a)(4), HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, DSTU Release 2.1, and
    • § 170.205(a)(5), HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2 Companion Guide, Release 2

 

      Correct Patient (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

 

      5. The user repeats steps 1-4, for each set of C-CDA R1.1, and C-CDA R2.1 xml files listed in the File Name for each of the health IT settings being certified.

Setup

  1. The tester creates a version in human readable format of the downloaded C-CDA R2 Release 2.1, in accordance with § 170.213 from step 1, of the System Under Test to be used for verification.
  2. The tester creates a human readable version of the downloaded C-CDA R2 Release 1.1, files from step 2, of the System Under Test to be used for verification.

Correct Patient

  1. The tester uses visual inspection to verify the Health IT Module can receive the C-CDA document downloaded in step 1, of the System Under Test as a C-CDA Release 1.1, document formatted according to the standard specified in § 170.205(a)(3) as either a CCD or a C-CDA with no specific document template.
  2. The tester uses visual inspection to verify the Health IT Module can receive the C-CDA document downloaded in step 2, of the System Under Test as a C-CDA Release 2.1, document formatted according to the standard specified in § 170.205(a)(4) using one of the following document templates:
    • CCD;
    • Referral Note; and
    • Inpatient setting only: Discharge Summary.
  3. Using the Health IT Module and the human readable xml files from steps 1 and 2, the tester verifies that each of the received C-CDA Release 1.1 and Release 2.1, documents can be properly matched to the correct patient record.

Paragraph (b)(2)(iii)(A)

System Under Test

Simultaneous Display

  1. Using the ETT: Message Validators –C-CDA R2.1 2015 Edition Cures Update, the user downloads the Clinical Information Reconciliation documents (xml) by selecting the receiver “170.315_b2_CIRI_Amb” or “170.315_b2_CIRI_Inp” criteria and the required Clinical Information Reconciliation documents xml files for both C-CDA R1.1 and R2.1 and executes the download.
  2. The user simultaneously views data (including active medications, allergies and intolerances, and problems) along with the source and last modification date attributes from at least two sources:
  • The current patient record which includes the base input received in section (b)(2)(ii); and
  • The Transition of Care Summary/Referral Summary C-CDA R1.1 and R2.1 document, formatted according to the standard adopted at:
  • § 170.205(a)(3) HL7® Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1, and
  • § 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, DSTU Release 2.1, and
  • § 170.205(a)(5) HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2 Companion Guide, Release 2, which includes the reconciliation data 170.315_b2_ciri_r11_ sample*_recon*.xml or 170.315_b2_ciri_r21_ sample*_recon*.xml

 

     Simultaneous Display (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

 

Note that Health IT Module will need to separately demonstrate the ability to reconcile summary of care documents formatted according to § 170.205(a)(3), § 170.205(a)(4), and  will need to separately demonstrate each of the following document templates: CCD or C-CDA with no specific document template for C-CDA R1.1, and CCD, Referral Note, and (inpatient setting only) Discharge Summary document templates for C-CDA R2.1 in accordance with the standard specified at § 170.213 for the health IT setting(s) being certified.

Test Lab Verification

Simultaneous Display

  1. The tester verifies data from multiple sources can be simultaneously displayed in a single view for medications, allergies and intolerances, and problems, including both the source and last modification date. The last modification date is defined for each list as:
    • Last date medication was documented or edited;
    • Last date the problem was documented or edited; and
    • Last date the allergies and intolerances were documented or edited.
  2. Further, the tester must verify the Health IT Module can display the current patient record and a Transition of Care Summary/Referral Summary C-CDA R1.1 and R2.1, document, formatted according to the standard adopted at § 170.205(a)(3) and separately the current patient record and a Transition of Care Summary/Referral Summary C-CDA document, formatted according to the standard adopted at § 170.205(a)(4) and § 170.205(a)(5).

Note: The tester must verify this can be completed for the CCD or C-CDA with no specific document template for C-CDA R1.1; and CCD, Referral Note, and (inpatient setting only) Discharge Summary document templates for C-CDA R2.1.

System Under Test Test Lab Verification

Simultaneous Display

  1. Using the ETT: Message Validators –C-CDA R2.1 2015 Edition Cures Update, the user downloads the Clinical Information Reconciliation documents (xml) by selecting the receiver “170.315_b2_CIRI_Amb” or “170.315_b2_CIRI_Inp” criteria and the required Clinical Information Reconciliation documents xml files for both C-CDA R1.1 and R2.1 and executes the download.
  2. The user simultaneously views data (including active medications, allergies and intolerances, and problems) along with the source and last modification date attributes from at least two sources:
  • The current patient record which includes the base input received in section (b)(2)(ii); and
  • The Transition of Care Summary/Referral Summary C-CDA R1.1 and R2.1 document, formatted according to the standard adopted at:
  • § 170.205(a)(3) HL7® Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1, and
  • § 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, DSTU Release 2.1, and
  • § 170.205(a)(5) HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2 Companion Guide, Release 2, which includes the reconciliation data 170.315_b2_ciri_r11_ sample*_recon*.xml or 170.315_b2_ciri_r21_ sample*_recon*.xml

 

     Simultaneous Display (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

 

Note that Health IT Module will need to separately demonstrate the ability to reconcile summary of care documents formatted according to § 170.205(a)(3), § 170.205(a)(4), and  will need to separately demonstrate each of the following document templates: CCD or C-CDA with no specific document template for C-CDA R1.1, and CCD, Referral Note, and (inpatient setting only) Discharge Summary document templates for C-CDA R2.1 in accordance with the standard specified at § 170.213 for the health IT setting(s) being certified.

Simultaneous Display

  1. The tester verifies data from multiple sources can be simultaneously displayed in a single view for medications, allergies and intolerances, and problems, including both the source and last modification date. The last modification date is defined for each list as:
    • Last date medication was documented or edited;
    • Last date the problem was documented or edited; and
    • Last date the allergies and intolerances were documented or edited.
  2. Further, the tester must verify the Health IT Module can display the current patient record and a Transition of Care Summary/Referral Summary C-CDA R1.1 and R2.1, document, formatted according to the standard adopted at § 170.205(a)(3) and separately the current patient record and a Transition of Care Summary/Referral Summary C-CDA document, formatted according to the standard adopted at § 170.205(a)(4) and § 170.205(a)(5).

Note: The tester must verify this can be completed for the CCD or C-CDA with no specific document template for C-CDA R1.1; and CCD, Referral Note, and (inpatient setting only) Discharge Summary document templates for C-CDA R2.1.

Paragraph (b)(2)(iii)(B)

System Under Test

The user creates a single, reconciled list using the data reviewed from the multiple medications, problems, or allergies and intolerances list sources in step one for each of the following:

  • Medications;
  • Allergies and Intolerances; and
  • Problems.
Test Lab Verification

The tester verifies that, for each list type: a simultaneous display (i.e. a single view), duplicates can be consolidated into a single representation, list items can be removed, and any other methods the Health IT Module may use to reconcile the list. The entire reconciliation process must occur within a simultaneous view.

System Under Test Test Lab Verification

The user creates a single, reconciled list using the data reviewed from the multiple medications, problems, or allergies and intolerances list sources in step one for each of the following:

  • Medications;
  • Allergies and Intolerances; and
  • Problems.

The tester verifies that, for each list type: a simultaneous display (i.e. a single view), duplicates can be consolidated into a single representation, list items can be removed, and any other methods the Health IT Module may use to reconcile the list. The entire reconciliation process must occur within a simultaneous view.

Paragraph (b)(2)(iii)(C)

System Under Test

The user reviews the details of the reconciled list and validates its accuracy.

Test Lab Verification

The tester verifies that, for each list type, the user is able to review and verify the accuracy of the final list.

System Under Test Test Lab Verification

The user reviews the details of the reconciled list and validates its accuracy.

The tester verifies that, for each list type, the user is able to review and verify the accuracy of the final list.

Paragraph (b)(2)(iii)(D)

System Under Test

The user accepts the reconciled list and the patient record in the Health IT Module is updated.

Test Lab Verification

The tester verifies that reconciled medications, allergies and intolerances, and problems data are accurately incorporated into the patient record and expressed in the following:

  • Medications are expressed according to the standard specified in § 170.213;
  • Allergies and intolerances are expressed according to the standard specified in § 170.213; and
  • Problems are expressed according to the standard specified in § 170.213.
System Under Test Test Lab Verification

The user accepts the reconciled list and the patient record in the Health IT Module is updated.

The tester verifies that reconciled medications, allergies and intolerances, and problems data are accurately incorporated into the patient record and expressed in the following:

  • Medications are expressed according to the standard specified in § 170.213;
  • Allergies and intolerances are expressed according to the standard specified in § 170.213; and
  • Problems are expressed according to the standard specified in § 170.213.

Paragraph (b)(2)(iv)

System Under Test
  1. For each reconciliation in section (b)(2)(iii), the user creates a CCD that includes the reconciled and incorporated data, in accordance with the standard adopted at § 170.205(a)(4) and § 170.205(a)(5), for each of the following:
    • Medications;
    • Allergies and Intolerances; and
    • Problems.

 

      (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022
Test Lab Verification

  1. Using the reconciled CCD document submitted by the System Under Test, the tester uses the ETT: Message Validators –C-CDA R2.1 2015 Edition Cures Update to upload the submitted CCD by selecting the sender “170.315_b2_CIRI_Amb” or “170.315_b2_CIRI_Inp” criteria, and the file name corresponding to the reconciliation input samples. The tester executes the upload. The tester uses the ETT: Message Validators Validation Report created as a result of the upload in step 1, to verify the Health IT Module passes without error to confirm that the Clinical Information Reconciliation CCD document is conformant when it is created after a reconciliation of medications, allergies and intolerances, and/or problems has been performed. Furthermore, the tester verifies that the Health IT Module meets the standard specified in § 170.205(a)(4) and § 170.205(a)(5).

    This verification is only for C-CDA R2.1 CCD documents.
System Under Test Test Lab Verification
  1. For each reconciliation in section (b)(2)(iii), the user creates a CCD that includes the reconciled and incorporated data, in accordance with the standard adopted at § 170.205(a)(4) and § 170.205(a)(5), for each of the following:
    • Medications;
    • Allergies and Intolerances; and
    • Problems.

 

      (Approved SVAP Version)

  • Complete steps above using Edge Testing Tool (ETT) Message Validator: R2.1 2015 Edition Cures Update and SVAP 2022 for HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

  1. Using the reconciled CCD document submitted by the System Under Test, the tester uses the ETT: Message Validators –C-CDA R2.1 2015 Edition Cures Update to upload the submitted CCD by selecting the sender “170.315_b2_CIRI_Amb” or “170.315_b2_CIRI_Inp” criteria, and the file name corresponding to the reconciliation input samples. The tester executes the upload. The tester uses the ETT: Message Validators Validation Report created as a result of the upload in step 1, to verify the Health IT Module passes without error to confirm that the Clinical Information Reconciliation CCD document is conformant when it is created after a reconciliation of medications, allergies and intolerances, and/or problems has been performed. Furthermore, the tester verifies that the Health IT Module meets the standard specified in § 170.205(a)(4) and § 170.205(a)(5).

    This verification is only for C-CDA R2.1 CCD documents.
Updated on 04-06-2022
Version # Description of Change Version Date
1.0

Initial Publication
06-15-2020
1.1

Updated compliance date per the Interim Final Rule (IFR), Information Blocking and the ONC Health IT Certification Program: Extension of Compliance Dates and Timeframes in Response to the COVID-19 Public Health Emergency. 
11-02-2020
1.2

Updated the technical outcome clarification for allergies and intolerances to be aligned with USCDI V1 allergies and intolerances elements per 21st Century Cures Act
04-06-2022
Regulation Text
Regulation Text

§ 170.315 (b)(2) Clinical information and reconciliation and incorporation—

  1. General requirements. Paragraphs (b)(2)(ii) and (iii) of this section must be completed based on the receipt of a transition of care/referral summary formatted in accordance with the standards adopted in § 170.205(a)(3) through (5) using the Continuity of Care Document, Referral Note, and (inpatient setting only) Discharge Summary document templates on and after December 31, 2022.
  2. Correct patient. Upon receipt of a transition of care/referral summary formatted according to the standards adopted § 170.205(a)(3) through (5), technology must be able to demonstrate that the transition of care/referral summary received can be properly matched to the correct patient.
  3. Reconciliation. Enable a user to reconcile the data that represent a patient's active medication list, allergies and intolerance list, and problem list as follows. For each list type:
    1. Simultaneously display (i.e., in a single view) the data from at least two sources in a manner that allows a user to view the data and their attributes, which must include, at a minimum, the source and last modification date.
    2. Enable a user to create a single reconciled list of each of the following: Medications; Allergies and Intolerances; and problems.
    3. Enable a user to review and validate the accuracy of a final set of data.
    4. Upon a user's confirmation, automatically update the list, and incorporate the following data expressed according to the specified standard(s) on and after December 31, 2022:
      1. Medications. At a minimum, the version of the standard specified in § 170.213;
      2. Allergies and intolerance. At a minimum, the version of the standard specified in § 170.213; and
      3. Problems. At a minimum, the version of the standard specified in § 170.213.
  4. System verification. Based on the data reconciled and incorporated, the technology must be able to create a file formatted according to the standard specified in § 170.205(a)(4) using the Continuity of Care Document template and the standard specified in § 170.205(a)(5) on and after December 31, 2022.
Standard(s) Referenced

Paragraphs (b)(2)(i) and (ii)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

§ 170.205(a)(3) Health Level 7 (HL7®)  Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1 (US Realm) Draft Standard for Trial Use July 2012

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

Paragraphs (b)(2)(iii)(B) – (D)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

Paragraph (b)(2)(iv)

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

 

Standards Version Advancement Process (SVAP) Version(s) Approved 

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 4.1 - US Realm, June 2023

§ 170.213 United States Core Data for Interoperability (USCDI), Version 3, October 2022 Errata

The following are available for certification until December 31, 2023:

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

§ 170.213 United States Core Data for Interoperability (USCDI), Version 2, July 2021

For more information, please visit the Standards Version Advancement Process (SVAP) Version(s) page.

Resource Documents
Resource Document
Revision History
Version # Description of Change Version Date
1.0

Initial Publication
06-15-2020
1.1

Updated compliance date per the Interim Final Rule (IFR), Information Blocking and the ONC Health IT Certification Program: Extension of Compliance Dates and Timeframes in Response to the COVID-19 Public Health Emergency. 
11-02-2020
1.2

Updated the technical outcome clarification for allergies and intolerances to be aligned with USCDI V1 allergies and intolerances elements per 21st Century Cures Act
04-06-2022
Regulation Text
Regulation Text

§ 170.315 (b)(2) Clinical information and reconciliation and incorporation—

  1. General requirements. Paragraphs (b)(2)(ii) and (iii) of this section must be completed based on the receipt of a transition of care/referral summary formatted in accordance with the standards adopted in § 170.205(a)(3) through (5) using the Continuity of Care Document, Referral Note, and (inpatient setting only) Discharge Summary document templates on and after December 31, 2022.
  2. Correct patient. Upon receipt of a transition of care/referral summary formatted according to the standards adopted § 170.205(a)(3) through (5), technology must be able to demonstrate that the transition of care/referral summary received can be properly matched to the correct patient.
  3. Reconciliation. Enable a user to reconcile the data that represent a patient's active medication list, allergies and intolerance list, and problem list as follows. For each list type:
    1. Simultaneously display (i.e., in a single view) the data from at least two sources in a manner that allows a user to view the data and their attributes, which must include, at a minimum, the source and last modification date.
    2. Enable a user to create a single reconciled list of each of the following: Medications; Allergies and Intolerances; and problems.
    3. Enable a user to review and validate the accuracy of a final set of data.
    4. Upon a user's confirmation, automatically update the list, and incorporate the following data expressed according to the specified standard(s) on and after December 31, 2022:
      1. Medications. At a minimum, the version of the standard specified in § 170.213;
      2. Allergies and intolerance. At a minimum, the version of the standard specified in § 170.213; and
      3. Problems. At a minimum, the version of the standard specified in § 170.213.
  4. System verification. Based on the data reconciled and incorporated, the technology must be able to create a file formatted according to the standard specified in § 170.205(a)(4) using the Continuity of Care Document template and the standard specified in § 170.205(a)(5) on and after December 31, 2022.
Standard(s) Referenced

Paragraphs (b)(2)(i) and (ii)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

§ 170.205(a)(3) Health Level 7 (HL7®)  Implementation Guide for CDA® Release 2: IHE Health Story Consolidation, DSTU Release 1.1 (US Realm) Draft Standard for Trial Use July 2012

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

Paragraphs (b)(2)(iii)(B) – (D)

§ 170.213 United States Core Data for Interoperability (USCDI), Version 1

Paragraph (b)(2)(iv)

§ 170.205(a)(4) HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm), Draft Standard for Trial Use Release 2.1 August 2015, June 2019 (with Errata)

§ 170.205(a)(5) HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 2, October 2019, IBR approved for § 170.205(a)(5)

 

Standards Version Advancement Process (SVAP) Version(s) Approved 

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 4.1 - US Realm, June 2023

§ 170.213 United States Core Data for Interoperability (USCDI), Version 3, October 2022 Errata

The following are available for certification until December 31, 2023:

§ 170.205(a)(5) HL7® CDA® R2 Implementation Guide: C-CDA Templates for Clinical Notes R2.1 Companion Guide, Release 3-US Realm, May 2022

§ 170.213 United States Core Data for Interoperability (USCDI), Version 2, July 2021

For more information, please visit the Standards Version Advancement Process (SVAP) Version(s) page.

Testing
Testing Tool

 

 

Edge Testing Tool (ETT): Message Validators

 

 

Test Tool Documentation

Test Tool Supplemental Guide

Criterion Subparagraph Test Data
(b)(2)(ii)

170.315_b2_ciri_r11_sample*.xml (All Samples)

170.315_b2_ciri_r21_sample*.xml (All Samples)
(b)(2)(iii)

170.315_b2_ciri_r11_sample*.xml (All Samples)

170.315_b2_ciri_r11_ sample*_recon*.xml (All Samples)

170.315_b2_ciri_r21_sample*.xml (All Samples)

170.315_b2_ciri_r21_sample*_recon*.xml (All Samples)

Certification Companion Guide: Clinical information reconciliation and incorporation

This Certification Companion Guide (CCG) is an informative document designed to assist with health IT product development. The CCG is not a substitute for the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program Final Rule (ONC Cures Act Final Rule). It extracts key portions of the rule’s preamble and includes subsequent clarifying interpretations. To access the full context of regulatory intent please consult the ONC Cures Act Final Rule or other included regulatory reference. The CCG is for public use and should not be sold or redistributed.

Link to ONC Cures Act Final Rule Preamble
Link to Interim Final Rule

 

Base EHR Definition In Scope for CEHRT Definition Real World Testing USCDI SVAP
Not Included Yes Yes Yes Yes
Certification Requirements

Privacy and Security: This certification criterion was adopted at § 170.315(b)(2). As a result, an ONC Authorized Certification Body (ONC-ACB) must ensure that a product presented for certification to a § 170.315(b) criterion includes the privacy and security criteria (adopted in § 170.315(d)) within the overall scope of the certificate issued to the product.

  • The privacy and security criteria (adopted in § 170.315(d)) do not need to be explicitly tested with this specific paragraph (b) criterion unless it is the only criterion for which certification is requested.
  • As a general rule, a product presented for certification only needs to be tested once to each applicable privacy and security criterion (adopted in § 170.315(d)) so long as the health IT developer attests that such privacy and security capabilities apply to the full scope of capabilities included in the requested certification. However, exceptions exist for § 170.315(e)(1) “View, download, and transmit to 3rd party (VDT)” and (e)(2) “Secure messaging”, which are explicitly stated.
Table for Privacy and Security

Design and Performance: The following design and performance certification criteria (adopted in § 170.315(g)) must also be certified in order for the product to be certified.

  • Safety-enhanced design (§ 170.315(g)(3)) must be explicitly demonstrated for this criterion.
  • When a single quality management system (QMS) is used, the QMS only needs to be identified once. Otherwise, when different QMS are used, each QMS needs to be separately identified for every capability to which it was applied.
  • When a single accessibility-centered design standard is used, the standard only needs to be identified once. Otherwise, the accessibility-centered design standards need to be identified for every capability to which they were applied; or, alternatively, the developer must state that no accessibility-centered design was used.
  • Consolidated Clinical Document Architecture (C-CDA) creation performance (§ 170.315(g)(6)) does not need to be explicitly tested with this criterion unless it is the only criterion within the scope of the requested certification that includes C-CDA creation capabilities. Note that the application of § 170.315(g)(6) depends on the C-CDA templates explicitly required by the C-CDA-referenced criterion or criteria included within the scope of the certificate sought. Please refer to the C-CDA creation performance CCG for more details.
Table for Design and Performance
Certification Requirements

Privacy and Security: This certification criterion was adopted at § 170.315(b)(2). As a result, an ONC Authorized Certification Body (ONC-ACB) must ensure that a product presented for certification to a § 170.315(b) criterion includes the privacy and security criteria (adopted in § 170.315(d)) within the overall scope of the certificate issued to the product.

  • The privacy and security criteria (adopted in § 170.315(d)) do not need to be explicitly tested with this specific paragraph (b) criterion unless it is the only criterion for which certification is requested.
  • As a general rule, a product presented for certification only needs to be tested once to each applicable privacy and security criterion (adopted in § 170.315(d)) so long as the health IT developer attests that such privacy and security capabilities apply to the full scope of capabilities included in the requested certification. However, exceptions exist for § 170.315(e)(1) “View, download, and transmit to 3rd party (VDT)” and (e)(2) “Secure messaging”, which are explicitly stated.

Design and Performance: The following design and performance certification criteria (adopted in § 170.315(g)) must also be certified in order for the product to be certified.

  • Safety-enhanced design (§ 170.315(g)(3)) must be explicitly demonstrated for this criterion.
  • When a single quality management system (QMS) is used, the QMS only needs to be identified once. Otherwise, when different QMS are used, each QMS needs to be separately identified for every capability to which it was applied.
  • When a single accessibility-centered design standard is used, the standard only needs to be identified once. Otherwise, the accessibility-centered design standards need to be identified for every capability to which they were applied; or, alternatively, the developer must state that no accessibility-centered design was used.
  • Consolidated Clinical Document Architecture (C-CDA) creation performance (§ 170.315(g)(6)) does not need to be explicitly tested with this criterion unless it is the only criterion within the scope of the requested certification that includes C-CDA creation capabilities. Note that the application of § 170.315(g)(6) depends on the C-CDA templates explicitly required by the C-CDA-referenced criterion or criteria included within the scope of the certificate sought. Please refer to the C-CDA creation performance CCG for more details.
Table for Privacy and Security
Table for Design and Performance
Technical Explanations and Clarifications

 

Applies to entire criterion

Clarifications:

  • The scope of this criterion is limited to the C-CDA Continuity of Care Document (CCD), Referral Note, and (inpatient setting only) Discharge Summary document templates. [see also 80 FR 62639]
  • In combination with the C-CDA R2.1 standard, developers certifying to the USCDI must follow the guidance and templates provided in HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2 Companion Guide, Release 2 for implementation of the C-CDA Release 2.1 standard. For example, details on how to structure and exchange Clinical Notes are included in the C-CDA Companion Guide.
  • “Incorporation” means to electronically process structured information from another source such that it is combined (in structured form) with information maintained by health IT and is subsequently available for use within the health IT system by a user. [see also 77 FR 54168 and 77 FR 54218]
  • In order to mitigate potential interoperability errors and inconsistent implementation of the HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, Draft Standard for Trial Use, Release 2.1, ONC assesses, approves, and incorporates corrections as part of required testing and certification to this criterion. [see the ONC Health IT Certification Program Overview] Certified health IT adoption of, and compliance with, the corrections are necessary because they update vocabularies, update rules for cardinality and conformance statements, and promote proper exchange of C-CDA documents. There is a 90-day delay from the time the CCG has been updated with the ONC-approved corrections to when compliance with the corrections will be required to pass testing (i.e., C-CDA 2.1 Validator). Similarly, there will be an 18-month delay before a finding of a correction’s absence in certified health IT during surveillance would constitute a non-conformity under the Certification Program.
  • Compliance date updated to December 31, 2022, per IFR.

 

Applies to entire criterion

Clarifications:

  • The scope of this criterion is limited to the C-CDA Continuity of Care Document (CCD), Referral Note, and (inpatient setting only) Discharge Summary document templates. [see also 80 FR 62639]
  • In combination with the C-CDA R2.1 standard, developers certifying to the USCDI must follow the guidance and templates provided in HL7® CDA® R2 IG: C-CDA Templates for Clinical Notes R2 Companion Guide, Release 2 for implementation of the C-CDA Release 2.1 standard. For example, details on how to structure and exchange Clinical Notes are included in the C-CDA Companion Guide.
  • “Incorporation” means to electronically process structured information from another source such that it is combined (in structured form) with information maintained by health IT and is subsequently available for use within the health IT system by a user. [see also 77 FR 54168 and 77 FR 54218]
  • In order to mitigate potential interoperability errors and inconsistent implementation of the HL7® Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes, Draft Standard for Trial Use, Release 2.1, ONC assesses, approves, and incorporates corrections as part of required testing and certification to this criterion. [see the ONC Health IT Certification Program Overview] Certified health IT adoption of, and compliance with, the corrections are necessary because they update vocabularies, update rules for cardinality and conformance statements, and promote proper exchange of C-CDA documents. There is a 90-day delay from the time the CCG has been updated with the ONC-approved corrections to when compliance with the corrections will be required to pass testing (i.e., C-CDA 2.1 Validator). Similarly, there will be an 18-month delay before a finding of a correction’s absence in certified health IT during surveillance would constitute a non-conformity under the Certification Program.
  • Compliance date updated to December 31, 2022, per IFR.

Paragraph (b)(2)(i)

Clarifications:

  • ONC is requiring Health IT Modules to be able to reconcile and incorporate information from C-CDAs formatted to both C-CDA Releases 1.1 and 2.1. While Release 2.1 largely ensures compatibility between C-CDA Release 1.1 and 2.0, it does not guarantee compatibility without further development effort. [see also 80 FR 62639]

Paragraph (b)(2)(i)

Clarifications:

  • ONC is requiring Health IT Modules to be able to reconcile and incorporate information from C-CDAs formatted to both C-CDA Releases 1.1 and 2.1. While Release 2.1 largely ensures compatibility between C-CDA Release 1.1 and 2.0, it does not guarantee compatibility without further development effort. [see also 80 FR 62639]

Paragraph (b)(2)(ii)

Technical outcome – The health IT can properly match a received transition of care (ToC)/referral summary (for both Releases 1.1 and 2.1) to the correct patient.

Clarifications:

  • Health IT Modules do not have to auto-match the patient. Manual patient match is acceptable as long as the received C-CDA can be matched to the correct patient. [see also 80 FR 62640 and 77 FR 54219]

Paragraph (b)(2)(ii)

Technical outcome – The health IT can properly match a received transition of care (ToC)/referral summary (for both Releases 1.1 and 2.1) to the correct patient.

Clarifications:

  • Health IT Modules do not have to auto-match the patient. Manual patient match is acceptable as long as the received C-CDA can be matched to the correct patient. [see also 80 FR 62640 and 77 FR 54219]

Paragraph (b)(2)(iii)(A)

Technical outcome – A user can simultaneously display a patient’s active data, and its attributes, from at least two of the following sources: a patient’s medication list, allergies and intolerances list, and problem list. Displayed data attributes must include the source and the last modification date.

Clarifications:

  • A vendor must enable a user to electronically and simultaneously display (that is, in a single view) the data from at least two list sources. If the two lists cannot be displayed in the tool at the same time, then this does not constitute a single view and does not meet the requirements for the certification criterion.

Paragraph (b)(2)(iii)(A)

Technical outcome – A user can simultaneously display a patient’s active data, and its attributes, from at least two of the following sources: a patient’s medication list, allergies and intolerances list, and problem list. Displayed data attributes must include the source and the last modification date.

Clarifications:

  • A vendor must enable a user to electronically and simultaneously display (that is, in a single view) the data from at least two list sources. If the two lists cannot be displayed in the tool at the same time, then this does not constitute a single view and does not meet the requirements for the certification criterion.

Paragraphs (b)(2)(iii)(B) - (D)

Technical outcome – A user can review, validate, and incorporate a patient’s medication list (using RxNorm), allergies and intolerances list (Medication using RxNorm, Drug Class using SNOMED CT®, and Reaction using SNOMED CT®), and problem list (using SNOMED CT®).

Clarifications:

  • The health IT can enable a user to review, validate, and incorporate medications, medication allergies, and problems in distinct functions, or combined, as long as all three can be demonstrated. [see also 80 FR 62639]
  • Testing will evaluate health IT ability to incorporate data from C-CDA documents with variations in the data elements to be reconciled to test real-world variation that may be found in C-CDA documents. [see also 80 FR 62639]
  • ONC encourages health IT developers to incorporate data in a structured format. [see also 77 FR 54219]
  • Incorporation does not have to be automated. [see also 77 FR 54219]
  • Health IT Modules can present for certification to a more recent version of RxNorm than what is currently in USCDI v1 per ONC’s policy that permits certification to a more recent version of certain vocabulary standards. [see also 80 FR 62620]
  • Health IT Modules can present for certification to a more recent version of SNOMED CT®, U.S. Edition than what is currently in USCDI v1 per ONC’s policy that permits certification to a more recent version of certain vocabulary standards. [see also 80 FR 62620]
  • ONC provides the following object identifiers (OIDs) to assist developers in the proper identification and exchange of health information coded to certain vocabulary standards.
    • RxNorm OID: 2.16.840.1.113883.6.88.
    • SNOMED CT® OID: 2.16.840.1.113883.6.96. [see also 80 FR 62612]

Paragraphs (b)(2)(iii)(B) - (D)

Technical outcome – A user can review, validate, and incorporate a patient’s medication list (using RxNorm), allergies and intolerances list (Medication using RxNorm, Drug Class using SNOMED CT®, and Reaction using SNOMED CT®), and problem list (using SNOMED CT®).

Clarifications:

  • The health IT can enable a user to review, validate, and incorporate medications, medication allergies, and problems in distinct functions, or combined, as long as all three can be demonstrated. [see also 80 FR 62639]
  • Testing will evaluate health IT ability to incorporate data from C-CDA documents with variations in the data elements to be reconciled to test real-world variation that may be found in C-CDA documents. [see also 80 FR 62639]
  • ONC encourages health IT developers to incorporate data in a structured format. [see also 77 FR 54219]
  • Incorporation does not have to be automated. [see also 77 FR 54219]
  • Health IT Modules can present for certification to a more recent version of RxNorm than what is currently in USCDI v1 per ONC’s policy that permits certification to a more recent version of certain vocabulary standards. [see also 80 FR 62620]
  • Health IT Modules can present for certification to a more recent version of SNOMED CT®, U.S. Edition than what is currently in USCDI v1 per ONC’s policy that permits certification to a more recent version of certain vocabulary standards. [see also 80 FR 62620]
  • ONC provides the following object identifiers (OIDs) to assist developers in the proper identification and exchange of health information coded to certain vocabulary standards.
    • RxNorm OID: 2.16.840.1.113883.6.88.
    • SNOMED CT® OID: 2.16.840.1.113883.6.96. [see also 80 FR 62612]

Paragraph (b)(2)(iv)

Technical outcome – The health IT can create a C-CDA document (using the CCD template in C-CDA Release 2.1) that includes the reconciled and incorporated data.

Clarifications:

  • No additional clarifications.

Paragraph (b)(2)(iv)

Technical outcome – The health IT can create a C-CDA document (using the CCD template in C-CDA Release 2.1) that includes the reconciled and incorporated data.

Clarifications:

  • No additional clarifications.